U.S. top court weighs patentability of human genes
NEW YORK Soon after learning that his son had autism, Hollywood producer Jon Shestack ("Air Force One") tried to get researchers investigating the genetic causes of the disorder to pool their DNA samples, the better to identify genes most likely to cause that disorder. But his approach to scientists at universities across the country in the late 1990s hit a brick wall: They refused to join forces, much less share the DNA.
"Each thought they needed to hold on to it to publish and patent," Shestack said in an interview. "This seemed criminal to us."
The U.S. Patent and Trademark Office has granted patents on at least 4,000 human genes to companies, universities and others that have discovered and decoded them. Patents now cover some 40 percent of the human genome, according to a scientific study led by Christopher Mason of Weill Cornell Medical College. But if foes of gene patents have their way, that percentage could be rolled back to zero.
On Monday, the U.S. Supreme Court will hear oral arguments in a case that calls into question whether human DNA can be claimed as intellectual property, and remain off limits to everyone without the permission of the patent holder.
The lawsuit, filed in 2009 by the American Civil Liberties Union and the Public Patent Foundation, challenges seven patents held by Myriad Genetics Inc on two human genes linked to breast and ovarian cancer. A federal judge said the patents were invalid. An appeals court overruled that decision, and the case landed in the Supreme Court.
The legal issues center on whether the genes that Myriad patented, called BRCA1 and BRCA2, are natural phenomena. The ACLU says human DNA is a product of nature, and as such not patentable under the Patent Act. Myriad argues that its patents are for genes that have been "isolated," which makes them products of human ingenuity and, therefore, patentable.
As scholars debate the legal questions, two parallel issues have emerged: whether patenting genes thwarts scientific research, and whether it harms patients.
A coalition of researchers, genetic counselors, cancer survivors, breast cancer support groups, and scientific associations representing 150,000 geneticists, pathologists and laboratory professionals argue that gene patents can be problematic on both counts. The American Medical Association, the American Society of Human Genetics, the March of Dimes and even James Watson (co-discoverer, in 1953, of the double helix), among others, have filed briefs asking the court to invalidate Myriad's patents on genes called BRCA1 and BRCA2.
On the other side are Myriad and industry groups such as the Biotechnology Industry Organization (BIO) and the Animal Health Institute, which say that if gene patenting is ruled invalid, companies - with no guarantee they could profit from their discoveries - would stop investing in genetics research, to the detriment not only of patients but the economy.
Gene patent opponents say studies and surveys show that such patents tie the hands of scientists and thwart research.
A 2010 investigation by an advisory committee to the U.S. Department of Health and Human Services found that patent holders had barred physicians and laboratories from offering genetic testing for hearing loss, leukemia, Alzheimer's, Huntington's disease, a heart condition called Long QT syndrome and other disorders affected by patented genes.
In a 2003 survey, 53 percent of the directors of genetics labs said they had given up some research due to gene-patent concerns. And in 2001, 49 percent of members of the American Society of Human Genetics said their research had to be limited due to gene patents.
"The overabundance of gene patents is a large and looming threat to personalized medicine," Cornell's Mason said. "How is it possible that my doctor cannot look at my DNA without being concerned about patent infringement? Individuals have an innate right to their own genome, or to allow their doctor to look at that genome, just like the lungs or kidneys."
Mark Capone, president of Myriad's laboratory division, counters that gene patents, by rewarding research, help patients. He said scientific research has not been hindered by the biotechnology company's patents, citing 18,000 scientists who have published 10,000 papers on BRCA.
"These are among the most studied genes in the world," Capone said.
"We've been able to save thousands of patients' lives" by telling patients they have cancer-causing BRCA mutations, he added.
The BIO industry group supports Myriad, saying patents are crucial to "the development of therapeutic, diagnostic, environmental, renewable energy, and agricultural products," and without patent protection such scientific discoveries would not be made.
The BRCA1 and BRCA2 genes account for most inherited forms of breast and ovarian cancer. They can be used to detect risk, and aid in treatment options.
Myriad has sole access to its proprietary database of BRCA sequences, which show whether a particular DNA change is dangerous. In 2004, Myriad stopped sharing that information with a breast cancer database run by the National Institutes of Health. Capone said the company was concerned that the information was being used not for research purposes, as intended, but to guide patient care.
Critics say the move has impeded research on BRCA, in particular studies to figure out the significance of rare variants and how such anomalies interact with other genes to increase or decrease the risk of cancer.
"Myriad's exclusive control has led to the misdiagnosis of patients and has precluded the deployment of improved genetic tests," said Lori Andrews, a law professor at Chicago-Kent College of Law, who wrote the American Medical Association's brief to the Supreme Court.
Geneticist Wendy Chung of Columbia University Medical Center cites the example of three sisters who sent their DNA samples to Myriad for BRCA analysis several years ago. The result was ambiguous: the women had a "variant of unknown significance" so they elected to have prophylactic mastectomies in case the mutation was cancer-causing. The women were very unhappy when, years later, Myriad re-classified the variant as innocuous.
"I think we could have moved a lot faster if the country's scientific brainpower could have analyzed patients' BRCA" rather than rely on Myriad, said Chung. Independent scientists could have studied not only whether a variant is dangerous or benign but also whether that risk is modified by the presence of other genes — crucial information when a woman is agonizing over whether to have her breasts removed, she said.
Capone said Myriad was not familiar with Chung's patients, but when a woman has a BRCA variant of unknown significance, the company recommends that she be treated according to her family history - aggressively if many close relatives have had breast or ovarian cancer, conservatively if not.
Myriad acknowledges that it has restricted what BRCA tests patients can get. For instance, since 1996 its standard test (which now costs $3,340) has looked for simple mutations in the BRCA genes, analogous to a misspelled word. Until 2006 it did not probe for large rearrangements in the DNA, which are analogous to moving big blocks of text from one page of a book to another.
The company, which has a market value of around $2.1 billion, has seen its shares fall about 13 percent since the Supreme Court decided on November 30 to take up the case.
It won a similar case in Australia in February, when the country's Federal Court ruled that Myriad and Melbourne-based Genetic Technologies Ltd had the right to hold a patent on BRCA1. Trial judge John Nicholas found the material could be subject to a patent because it could not exist naturally on its own, inside or outside the human body.
The Australian findings are unlikely to influence the U.S. case. Justice Nicholas said evidence presented in Australia was different to evidence in the U.S. case, and there were also different constitutional settings for patent laws.
The case is Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al
(The story refiles correcting paragraph 25 to read "Until 2006" ... instead of "Until last year.)
(Editing by Howard Goller, Tiffany Wu and Gunna Dickson)
NEW YORK Soon after learning that his son had autism, Hollywood producer Jon Shestack ("Air Force One") tried to get researchers investigating the genetic causes of the disorder to pool their DNA samples, the better to identify genes most likely
WASHINGTON U.S. Supreme Court justices on Monday signaled reluctance to issue too broad a ruling about patents on human genes, and some indicated they might seek a compromise distinguishing between types of genetic material. The biotechnology industr
WASHINGTON The Supreme Court justices on Monday signaled reluctance to issue too broad a ruling about patents on human genes, and some indicated they might seek a compromise distinguishing between types of genetic material. The biotechnology industry
BRUSSELS/LONDON Europe's top court has opened the door to certain stem cell patents in the European Union by ruling that an organism incapable of developing into a human being is not a human embryo and may be patented. Thursday's judgment by the Euro
WASHINGTON The Supreme Court rejected two patents on a method for monitoring a patient's blood to determine the best dosage for a drug, a decision that may affect the profitability of personalized medicine. The justices unanimously overturned on Tues
n">India's top court will hear final arguments from September 11 in a key patent dispute between Swiss drugmaker Novartis and India's patent office, a case that could curb India's global position as a supplier of cut-price generic medicines. The h
NEW DELHI Swiss drugmaker Novartis told India's top court it had demonstrated the improved efficacy of its cancer drug Glivec as the final hearing began on Tuesday of a patent case that could change the rules for the country's healthcare sector. A pa
NEW YORK Two human genes associated with breast and ovarian cancers cannot be patented because they are a product of nature, a federal judge ruled on Monday. The American Civil Liberties Union and other groups sued in May to invalidate a patent on tw
WASHINGTON The government urged the Supreme Court to rule in favor of a generic drugmaker in a case over how companies can fight brand-name rivals to get cheaper drugs to market. The nation's top court on Monday heard arguments about whether the gene
YouTube in Mitverschwörer öffentliche Debatte über die Corporate Patente auf menschliche Gene zum SchweigenYouTube, im Besitz von Corporate-Riese Google hat sich unser Video der Diskussion der Eigentumsverhältnisse von Patenten auf menschliche Gene verboten. Dieses Video, das für hochjubeln BRCA Brustkrebs-Gen-Tests und ein Teil der Billionen-Dollar-Indus
Nach den jüngsten Enthüllungen, wie doppelte Brustamputation PR Angelina Jolie Stunt - Feeds in den Gewinnen der Billionen - Dollar - Industrie , die menschliche Gene zu besitzen behauptet, ist Natural News fordert nun Jolie öffentlich Patente auf me
WASHINGTON The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices'
TEL AVIV Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favor regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday. Vigodman said in a confe
WASHINGTON The U.S. Supreme Court ruled on Tuesday in favor of a generic drugmaker in a case over how companies can fight brand-name rivals in an effort to get their cheaper medicines to market. The high court unanimously ruled that the generics comp
WASHINGTON The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B. The high court declined to hear Bristol-Myers' challenge to an appeals court ruli
NEW YORK Companies, trade groups and universities who fear that many important discoveries may no longer qualify for patents are among a broad coalition urging the U.S. Supreme Court to review the cancellation of a patent on a less risky form of pren
WASHINGTON The Supreme Court on Monday sent three patent cases, including one dispute over Shire Plc'sLialda drug, back to a lower court for further proceedings in light of a ruling the justices issued last week. All three cases will now be reconside
WASHINGTON The Supreme Court on Thursday set the schedule for briefs to be filed ahead of hearing arguments in late March over President Barack Obama's sweeping healthcare overhaul law. The high court agreed to a proposal by the three main parties in
WASHINGTON The patent on Merck & Co's cholesterol fighters Zetia and Vytorin, two of the drugmaker's biggest products, is valid, a U.S. appeals court ruled on Thursday. Vytorin combines Zocor, a member of the statin family developed by Merck, with a
WASHINGTON Supreme Court justices weighed on Tuesday whether makers of generic drugs already approved by the Food and Drug Administration can be held liable under state law for claims of design defects. During a one-hour oral argument justices questi
- 08-231Die Out-of-Body Electric
- 10-132Study charts links between mobile phones, tumors
- 05-053Fortgeschrittene Anfänger Marathon Trainingsplan
- 05-214Wie zu organisieren das Chaos Haus zu bewegen, wenn Sie sind Sehbehinderte
- 07-205Big Pharma Arzneimittelstudien verletzen kritisch sechs, so dass ein Gehirn tot; Mainstream-Medien zeigt Finger auf Marihuana nicht in Experiment verwendet
- 10-046Johanniskraut bei Depressionen
- 12-0174 Gründe, auch zur Übung, wenn es draußen kalt ist
- 03-038Warum wird mein neues Stomien so schlecht brennen am Morgen?
- 04-069Wird Osteo Bi-flex Ursache Verstopfung?
- 07-281Ist ein Benzo das Richtige für mich trotz ihrer guten Ruf?
- 08-042Slo-fe Absorptions wie lange dauert es im Bauch bleiben?
- 10-223Mayo Clinic Forscher neue Klasse von Medikamenten, die Entwicklung zur Behandlung von Diabetes
- 01-304Hat Einnahme Trazodon verursachen Bluthochdruck?
- 03-135Government to cut Texas women's health funds over abortion
- 07-14610 Muskeln, die Sie Blick groß
- 10-167Warum Ausrichtung Matters
- 04-148Muskelkrämpfe - Menschen, die aus periodischen Beinbewegung leiden, können Sie schlafen im selben Bett wie Ihr?
- 07-019Gibt es eine gute Alternative zu Linzess?
- Kann ich Aleive oder Advil mit Cefuroximaxetil nehmen?
- Pristiq funktioniert nicht auf 87 Jahre alten weiblichen !?
- Orabase mit Benzocain - Kann kontinuierliche Verwendung von oragel Zahnfleisch machen in eine Wunde ausbrechen?
- Die Probleme mit der Patentierung gentechnisch veränderte Lebensmittel
- Harnwegsinfektion - bestanden bilaterale Nierensteine ​​dreieinhalb Wochen. Ging zu?
- Kinder haben "erstaunlichen Fähigkeiten", dass Erwachsene Lack
- Challenging the Thin Ideal
- Was ist Elektrokrampftherapie (ECT)?
- Ist Borsäure schädlich für den Menschen eingeatmet, wenn sie versehentlich und wie viel Wenn ja?
- Wie schlimm ist es zu nehmen Benedryl, Tramadol, und zusammen Xanax?
- Glenn Close has genes mapped
- Kann Ursache Angstattacken Pradaxa?
- Systemischer Lupus erythematodes - Als ich mit sle diagnostiziert wurde studierte ich mehr über das zu verstehen?
- Pharmas, medizinische Gerätehersteller setzen bei CED Life Science Konferenz aufschlagen
- Kokain Rots Ihr Gehirn: Im Ernst, Heavy User mehr verlieren Gray Matter
- Chloe hält sich wie ein populärer Name
- Gout - Akut - Ist alchahol Gicht verursacht?
- Fixing Formel (Pulverisierte)
- Corned Warnungen anzuzeigen, dass Depressionen erhöhen kann, alle Informationen oder Erfahrungen? ----schneiden---- In Antwort auf 2009.10.26 18.15 bis suzanne66 Es ist bekannt, dass eine Nebenwirkung von Corticosteroiden Depression ist. Nebenwirkung
Erektile Dysfunktion - war ich bei einem Unfall 1 1/2 Jahre her, wo mein Becken in Folge geknackt wurde?... Mich zwischen meinem Auto und einem Zement mittleren Leitplanke auf der Autobahn (mein Auto durch einen halb getroffen wurde, während ich vor meinem Auto fixin einer Wohnung war) steckte werden, sowieso litt ich katastrophale Verletzungen an den
- WASHINGTON Arizona's controversial new law cracking down on illegal immigration could put doctors into a pickle, an Arizona physician said in a letter published in the New England Journal of Medicine Wednesday. Dr. Lucas Restrepo of the Barrow Neurol
- Zum Zeitpunkt des Schreibens, 5 Fluglotsen haben Einschlafen am Schalter gefunden worden. Zu der Zeit, dieses Stück geschrieben ist, einige andere haben die Schlummerparty verbunden. Denken Sie daran, Thereâ € ™ sa viel mehr dösen in den Türmen als W
- CINCINNATI, Ohio - Die Life-Science Inkubator biostart hat eine Initiative zu gewinnen und zu helfen , etwa ein halbes Dutzend Gesundheits-Dienstleistungsunternehmen ins Leben gerufen. Biostart werden Kleinkredite zwischen $ 5.000 bis $ 75.000 Execut
- Markieren Sie Ihr Portfolio In meinem vorherigen Blog: "Meine Meinung zu den Glück-The Need to Matter" Ich schrieb: "Sie können Geld und Juwelen haben, aber wenn man den Rand gedrängt fühlen, aus der Schleife werden Sie unglücklich sein.&qu
- n">Two more people have died from fungal meningitis linked to steroid injections, bringing the total to 14 deaths since the outbreak began last month, the U.S. Centers for Disease Control said on Thursday. A total of 170 people have been stricken
- Die Beckenbodenmuskeln sind die Grundlage für den Kern des Körpers. Sie helfen, das Becken zu stabilisieren, und sie unterstützen die Organe des unteren Bauchhöhle, wie die Blase und Gebärmutter. Die Beckenbodenmuskeln, zusammen mit den tiefen Muskel
- Ich bin 29 Jahre alt und 5'9 .. wenn ich 18 war ich schwanger und ich wog nur 115, und ich habe etwa 140 für den letzten 10 Jahren wog aber etwa 12 Monaten wog ich 140 und heute wog ich mich selbst und ich 114 war .. ich bin sehr gesunde Person, und
- Scheint, wie wenn ich darauf bin ich mit Nesselsucht ausbrechen, die so schlecht Juckreiz, ich aufhören Medikamente und es wird besser, aber nicht vollständig geklärt, es die Medikamente oder die Krankheit selbst sein könnte? ----schneiden---- In Ant
- Was zu nehmen, wenn Sie die Steven Johnson syndrom expierenced haben?
- Letzter Aufruf für den MedCity Nachrichten Leserumfrage. Nimm an der Umfrage teil!
- Anti-obesity proposal fails again at McDonald's
- Kranke Tage machen Arbeiter weniger wahrscheinlich On-the-Job-Verletzungen leiden
- Das follikuläre Lymphom - ist eine Operation im allgemeinen verwendet werden, wenn nicht, welche Behandlungen vorgeschlagen?
- Agoraphobia und PKWs
- Vor dem Kauf Robitussin Husten und Kälte CF
- Five Ways to Keep Logopädie gehen über Schule Breaks
- Iliotibialen Band Streckt